img

Global Myelodysplastic Syndrome (MDS) Treatment Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Myelodysplastic Syndrome (MDS) Treatment Market Research Report 2024

Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8.
According to Mr Accuracy reports new survey, global Myelodysplastic Syndrome (MDS) Treatment market is projected to reach US$ 6102.7 million in 2029, increasing from US$ 3270 million in 2022, with the CAGR of 9.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Myelodysplastic Syndrome (MDS) Treatment market research.
The global market for myelodysplastic syndrome (MDS) treatment is expected to grow significantly over the coming years, owing to rising pipeline products and product approvals, as well as increased R&D investments in the development of novel drugs for MDS. For instance, Inqovi (decitabine and cedazuridine) tablets were approved by the United States Food and Drug Administration in July 2020 for the treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This is a significant advancement in treatment options for patients with MDS, a type of blood cancer which previously required intravenous therapy at a healthcare facility. Thus, the aforementioned factors are anticipated to contribute to the growth of the myelodysplastic syndrome (MDS) treatment market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Myelodysplastic Syndrome (MDS) Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Novartis AG
Celgene Corporation
Otsuka Pharmaceutical Co., Ltd
Sandoz Inc
Dr Reddys Laboratories Limited
Pharmascience Inc
Accord Healthcare Ltd
Mylan N.V.
Takeda Pharmaceutical Company Limited
Bristol-Myers Squibb
LUPIN
Pfizer Inc
Amgen Inc
Onconova Therapeutics
Astex Pharmaceutical
Helsinn Healthcare SA
Abbott
Boehringer Ingelheim International GmbH,
Johnson & Johnson Private Limited.
MEI Pharma Inc.
Aprea Therapeutics
Reddy's Laboratories Ltd.
AbbVie Inc.
Syros Pharmaceuticals
Acceleron Pharma, Inc.
Segment by Type
Azacitidine
Lenalidomide
Decitabine
Deferasirox

Segment by Application


Refractory Cytopenia with Unilineage Dysplasia
Refractory Anemia with Ringed Sideroblasts
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Myelodysplastic Syndrome (MDS) Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Azacitidine
1.2.3 Lenalidomide
1.2.4 Decitabine
1.2.5 Deferasirox
1.3 Market by Application
1.3.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Refractory Cytopenia with Unilineage Dysplasia
1.3.3 Refractory Anemia with Ringed Sideroblasts
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Perspective (2018-2029)
2.2 Myelodysplastic Syndrome (MDS) Treatment Growth Trends by Region
2.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Myelodysplastic Syndrome (MDS) Treatment Historic Market Size by Region (2018-2024)
2.2.3 Myelodysplastic Syndrome (MDS) Treatment Forecasted Market Size by Region (2024-2029)
2.3 Myelodysplastic Syndrome (MDS) Treatment Market Dynamics
2.3.1 Myelodysplastic Syndrome (MDS) Treatment Industry Trends
2.3.2 Myelodysplastic Syndrome (MDS) Treatment Market Drivers
2.3.3 Myelodysplastic Syndrome (MDS) Treatment Market Challenges
2.3.4 Myelodysplastic Syndrome (MDS) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myelodysplastic Syndrome (MDS) Treatment Players by Revenue
3.1.1 Global Top Myelodysplastic Syndrome (MDS) Treatment Players by Revenue (2018-2024)
3.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Players (2018-2024)
3.2 Global Myelodysplastic Syndrome (MDS) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Myelodysplastic Syndrome (MDS) Treatment Revenue
3.4 Global Myelodysplastic Syndrome (MDS) Treatment Market Concentration Ratio
3.4.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myelodysplastic Syndrome (MDS) Treatment Revenue in 2022
3.5 Myelodysplastic Syndrome (MDS) Treatment Key Players Head office and Area Served
3.6 Key Players Myelodysplastic Syndrome (MDS) Treatment Product Solution and Service
3.7 Date of Enter into Myelodysplastic Syndrome (MDS) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by Type
4.1 Global Myelodysplastic Syndrome (MDS) Treatment Historic Market Size by Type (2018-2024)
4.2 Global Myelodysplastic Syndrome (MDS) Treatment Forecasted Market Size by Type (2024-2029)
5 Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by Application
5.1 Global Myelodysplastic Syndrome (MDS) Treatment Historic Market Size by Application (2018-2024)
5.2 Global Myelodysplastic Syndrome (MDS) Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Myelodysplastic Syndrome (MDS) Treatment Market Size (2018-2029)
6.2 North America Myelodysplastic Syndrome (MDS) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Myelodysplastic Syndrome (MDS) Treatment Market Size by Country (2018-2024)
6.4 North America Myelodysplastic Syndrome (MDS) Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Myelodysplastic Syndrome (MDS) Treatment Market Size (2018-2029)
7.2 Europe Myelodysplastic Syndrome (MDS) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Myelodysplastic Syndrome (MDS) Treatment Market Size by Country (2018-2024)
7.4 Europe Myelodysplastic Syndrome (MDS) Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Size (2018-2029)
8.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Size by Region (2018-2024)
8.4 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Myelodysplastic Syndrome (MDS) Treatment Market Size (2018-2029)
9.2 Latin America Myelodysplastic Syndrome (MDS) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Myelodysplastic Syndrome (MDS) Treatment Market Size by Country (2018-2024)
9.4 Latin America Myelodysplastic Syndrome (MDS) Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Market Size (2018-2029)
10.2 Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Market Size by Country (2018-2024)
10.4 Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis AG
11.1.1 Novartis AG Company Detail
11.1.2 Novartis AG Business Overview
11.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Introduction
11.1.4 Novartis AG Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.1.5 Novartis AG Recent Development
11.2 Celgene Corporation
11.2.1 Celgene Corporation Company Detail
11.2.2 Celgene Corporation Business Overview
11.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Introduction
11.2.4 Celgene Corporation Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.2.5 Celgene Corporation Recent Development
11.3 Otsuka Pharmaceutical Co., Ltd
11.3.1 Otsuka Pharmaceutical Co., Ltd Company Detail
11.3.2 Otsuka Pharmaceutical Co., Ltd Business Overview
11.3.3 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Introduction
11.3.4 Otsuka Pharmaceutical Co., Ltd Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.3.5 Otsuka Pharmaceutical Co., Ltd Recent Development
11.4 Sandoz Inc
11.4.1 Sandoz Inc Company Detail
11.4.2 Sandoz Inc Business Overview
11.4.3 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Introduction
11.4.4 Sandoz Inc Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.4.5 Sandoz Inc Recent Development
11.5 Dr Reddys Laboratories Limited
11.5.1 Dr Reddys Laboratories Limited Company Detail
11.5.2 Dr Reddys Laboratories Limited Business Overview
11.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Introduction
11.5.4 Dr Reddys Laboratories Limited Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.5.5 Dr Reddys Laboratories Limited Recent Development
11.6 Pharmascience Inc
11.6.1 Pharmascience Inc Company Detail
11.6.2 Pharmascience Inc Business Overview
11.6.3 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Introduction
11.6.4 Pharmascience Inc Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.6.5 Pharmascience Inc Recent Development
11.7 Accord Healthcare Ltd
11.7.1 Accord Healthcare Ltd Company Detail
11.7.2 Accord Healthcare Ltd Business Overview
11.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Introduction
11.7.4 Accord Healthcare Ltd Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.7.5 Accord Healthcare Ltd Recent Development
11.8 Mylan N.V.
11.8.1 Mylan N.V. Company Detail
11.8.2 Mylan N.V. Business Overview
11.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Introduction
11.8.4 Mylan N.V. Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.8.5 Mylan N.V. Recent Development
11.9 Takeda Pharmaceutical Company Limited
11.9.1 Takeda Pharmaceutical Company Limited Company Detail
11.9.2 Takeda Pharmaceutical Company Limited Business Overview
11.9.3 Takeda Pharmaceutical Company Limited Myelodysplastic Syndrome (MDS) Treatment Introduction
11.9.4 Takeda Pharmaceutical Company Limited Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.9.5 Takeda Pharmaceutical Company Limited Recent Development
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Company Detail
11.10.2 Bristol-Myers Squibb Business Overview
11.10.3 Bristol-Myers Squibb Myelodysplastic Syndrome (MDS) Treatment Introduction
11.10.4 Bristol-Myers Squibb Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.10.5 Bristol-Myers Squibb Recent Development
11.11 LUPIN
11.11.1 LUPIN Company Detail
11.11.2 LUPIN Business Overview
11.11.3 LUPIN Myelodysplastic Syndrome (MDS) Treatment Introduction
11.11.4 LUPIN Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.11.5 LUPIN Recent Development
11.12 Pfizer Inc
11.12.1 Pfizer Inc Company Detail
11.12.2 Pfizer Inc Business Overview
11.12.3 Pfizer Inc Myelodysplastic Syndrome (MDS) Treatment Introduction
11.12.4 Pfizer Inc Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.12.5 Pfizer Inc Recent Development
11.13 Amgen Inc
11.13.1 Amgen Inc Company Detail
11.13.2 Amgen Inc Business Overview
11.13.3 Amgen Inc Myelodysplastic Syndrome (MDS) Treatment Introduction
11.13.4 Amgen Inc Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.13.5 Amgen Inc Recent Development
11.14 Onconova Therapeutics
11.14.1 Onconova Therapeutics Company Detail
11.14.2 Onconova Therapeutics Business Overview
11.14.3 Onconova Therapeutics Myelodysplastic Syndrome (MDS) Treatment Introduction
11.14.4 Onconova Therapeutics Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.14.5 Onconova Therapeutics Recent Development
11.15 Astex Pharmaceutical
11.15.1 Astex Pharmaceutical Company Detail
11.15.2 Astex Pharmaceutical Business Overview
11.15.3 Astex Pharmaceutical Myelodysplastic Syndrome (MDS) Treatment Introduction
11.15.4 Astex Pharmaceutical Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.15.5 Astex Pharmaceutical Recent Development
11.16 Helsinn Healthcare SA
11.16.1 Helsinn Healthcare SA Company Detail
11.16.2 Helsinn Healthcare SA Business Overview
11.16.3 Helsinn Healthcare SA Myelodysplastic Syndrome (MDS) Treatment Introduction
11.16.4 Helsinn Healthcare SA Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.16.5 Helsinn Healthcare SA Recent Development
11.17 Abbott
11.17.1 Abbott Company Detail
11.17.2 Abbott Business Overview
11.17.3 Abbott Myelodysplastic Syndrome (MDS) Treatment Introduction
11.17.4 Abbott Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.17.5 Abbott Recent Development
11.18 Boehringer Ingelheim International GmbH,
11.18.1 Boehringer Ingelheim International GmbH, Company Detail
11.18.2 Boehringer Ingelheim International GmbH, Business Overview
11.18.3 Boehringer Ingelheim International GmbH, Myelodysplastic Syndrome (MDS) Treatment Introduction
11.18.4 Boehringer Ingelheim International GmbH, Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.18.5 Boehringer Ingelheim International GmbH, Recent Development
11.19 Johnson & Johnson Private Limited.
11.19.1 Johnson & Johnson Private Limited. Company Detail
11.19.2 Johnson & Johnson Private Limited. Business Overview
11.19.3 Johnson & Johnson Private Limited. Myelodysplastic Syndrome (MDS) Treatment Introduction
11.19.4 Johnson & Johnson Private Limited. Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.19.5 Johnson & Johnson Private Limited. Recent Development
11.20 MEI Pharma Inc.
11.20.1 MEI Pharma Inc. Company Detail
11.20.2 MEI Pharma Inc. Business Overview
11.20.3 MEI Pharma Inc. Myelodysplastic Syndrome (MDS) Treatment Introduction
11.20.4 MEI Pharma Inc. Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.20.5 MEI Pharma Inc. Recent Development
11.21 Aprea Therapeutics
11.21.1 Aprea Therapeutics Company Detail
11.21.2 Aprea Therapeutics Business Overview
11.21.3 Aprea Therapeutics Myelodysplastic Syndrome (MDS) Treatment Introduction
11.21.4 Aprea Therapeutics Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.21.5 Aprea Therapeutics Recent Development
11.22 Reddy's Laboratories Ltd.
11.22.1 Reddy's Laboratories Ltd. Company Detail
11.22.2 Reddy's Laboratories Ltd. Business Overview
11.22.3 Reddy's Laboratories Ltd. Myelodysplastic Syndrome (MDS) Treatment Introduction
11.22.4 Reddy's Laboratories Ltd. Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.22.5 Reddy's Laboratories Ltd. Recent Development
11.23 AbbVie Inc.
11.23.1 AbbVie Inc. Company Detail
11.23.2 AbbVie Inc. Business Overview
11.23.3 AbbVie Inc. Myelodysplastic Syndrome (MDS) Treatment Introduction
11.23.4 AbbVie Inc. Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.23.5 AbbVie Inc. Recent Development
11.24 Syros Pharmaceuticals
11.24.1 Syros Pharmaceuticals Company Detail
11.24.2 Syros Pharmaceuticals Business Overview
11.24.3 Syros Pharmaceuticals Myelodysplastic Syndrome (MDS) Treatment Introduction
11.24.4 Syros Pharmaceuticals Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.24.5 Syros Pharmaceuticals Recent Development
11.25 Acceleron Pharma, Inc.
11.25.1 Acceleron Pharma, Inc. Company Detail
11.25.2 Acceleron Pharma, Inc. Business Overview
11.25.3 Acceleron Pharma, Inc. Myelodysplastic Syndrome (MDS) Treatment Introduction
11.25.4 Acceleron Pharma, Inc. Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
11.25.5 Acceleron Pharma, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Myelodysplastic Syndrome (MDS) Treatment Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Azacitidine
Table 3. Key Players of Lenalidomide
Table 4. Key Players of Decitabine
Table 5. Key Players of Deferasirox
Table 6. Global Myelodysplastic Syndrome (MDS) Treatment Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Myelodysplastic Syndrome (MDS) Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Myelodysplastic Syndrome (MDS) Treatment Market Size by Region (2018-2024) & (US$ Million)
Table 9. Global Myelodysplastic Syndrome (MDS) Treatment Market Share by Region (2018-2024)
Table 10. Global Myelodysplastic Syndrome (MDS) Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Myelodysplastic Syndrome (MDS) Treatment Market Share by Region (2024-2029)
Table 12. Myelodysplastic Syndrome (MDS) Treatment Market Trends
Table 13. Myelodysplastic Syndrome (MDS) Treatment Market Drivers
Table 14. Myelodysplastic Syndrome (MDS) Treatment Market Challenges
Table 15. Myelodysplastic Syndrome (MDS) Treatment Market Restraints
Table 16. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Players (2018-2024) & (US$ Million)
Table 17. Global Myelodysplastic Syndrome (MDS) Treatment Market Share by Players (2018-2024)
Table 18. Global Top Myelodysplastic Syndrome (MDS) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome (MDS) Treatment as of 2022)
Table 19. Ranking of Global Top Myelodysplastic Syndrome (MDS) Treatment Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Myelodysplastic Syndrome (MDS) Treatment Revenue (CR5 and HHI) & (2018-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Myelodysplastic Syndrome (MDS) Treatment Product Solution and Service
Table 23. Date of Enter into Myelodysplastic Syndrome (MDS) Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Myelodysplastic Syndrome (MDS) Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 26. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Type (2018-2024)
Table 27. Global Myelodysplastic Syndrome (MDS) Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Type (2024-2029)
Table 29. Global Myelodysplastic Syndrome (MDS) Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 30. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Application (2018-2024)
Table 31. Global Myelodysplastic Syndrome (MDS) Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Application (2024-2029)
Table 33. North America Myelodysplastic Syndrome (MDS) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Myelodysplastic Syndrome (MDS) Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 35. North America Myelodysplastic Syndrome (MDS) Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Myelodysplastic Syndrome (MDS) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Myelodysplastic Syndrome (MDS) Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 38. Europe Myelodysplastic Syndrome (MDS) Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Size by Region (2018-2024) & (US$ Million)
Table 41. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Myelodysplastic Syndrome (MDS) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Myelodysplastic Syndrome (MDS) Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 44. Latin America Myelodysplastic Syndrome (MDS) Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 47. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 48. Novartis AG Company Detail
Table 49. Novartis AG Business Overview
Table 50. Novartis AG Myelodysplastic Syndrome (MDS) Treatment Product
Table 51. Novartis AG Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 52. Novartis AG Recent Development
Table 53. Celgene Corporation Company Detail
Table 54. Celgene Corporation Business Overview
Table 55. Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Product
Table 56. Celgene Corporation Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 57. Celgene Corporation Recent Development
Table 58. Otsuka Pharmaceutical Co., Ltd Company Detail
Table 59. Otsuka Pharmaceutical Co., Ltd Business Overview
Table 60. Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Product
Table 61. Otsuka Pharmaceutical Co., Ltd Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 62. Otsuka Pharmaceutical Co., Ltd Recent Development
Table 63. Sandoz Inc Company Detail
Table 64. Sandoz Inc Business Overview
Table 65. Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Product
Table 66. Sandoz Inc Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 67. Sandoz Inc Recent Development
Table 68. Dr Reddys Laboratories Limited Company Detail
Table 69. Dr Reddys Laboratories Limited Business Overview
Table 70. Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Product
Table 71. Dr Reddys Laboratories Limited Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 72. Dr Reddys Laboratories Limited Recent Development
Table 73. Pharmascience Inc Company Detail
Table 74. Pharmascience Inc Business Overview
Table 75. Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Product
Table 76. Pharmascience Inc Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 77. Pharmascience Inc Recent Development
Table 78. Accord Healthcare Ltd Company Detail
Table 79. Accord Healthcare Ltd Business Overview
Table 80. Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Product
Table 81. Accord Healthcare Ltd Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 82. Accord Healthcare Ltd Recent Development
Table 83. Mylan N.V. Company Detail
Table 84. Mylan N.V. Business Overview
Table 85. Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Product
Table 86. Mylan N.V. Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 87. Mylan N.V. Recent Development
Table 88. Takeda Pharmaceutical Company Limited Company Detail
Table 89. Takeda Pharmaceutical Company Limited Business Overview
Table 90. Takeda Pharmaceutical Company Limited Myelodysplastic Syndrome (MDS) Treatment Product
Table 91. Takeda Pharmaceutical Company Limited Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 92. Takeda Pharmaceutical Company Limited Recent Development
Table 93. Bristol-Myers Squibb Company Detail
Table 94. Bristol-Myers Squibb Business Overview
Table 95. Bristol-Myers Squibb Myelodysplastic Syndrome (MDS) Treatment Product
Table 96. Bristol-Myers Squibb Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 97. Bristol-Myers Squibb Recent Development
Table 98. LUPIN Company Detail
Table 99. LUPIN Business Overview
Table 100. LUPIN Myelodysplastic Syndrome (MDS) Treatment Product
Table 101. LUPIN Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 102. LUPIN Recent Development
Table 103. Pfizer Inc Company Detail
Table 104. Pfizer Inc Business Overview
Table 105. Pfizer Inc Myelodysplastic Syndrome (MDS) Treatment Product
Table 106. Pfizer Inc Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 107. Pfizer Inc Recent Development
Table 108. Amgen Inc Company Detail
Table 109. Amgen Inc Business Overview
Table 110. Amgen Inc Myelodysplastic Syndrome (MDS) Treatment Product
Table 111. Amgen Inc Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 112. Amgen Inc Recent Development
Table 113. Onconova Therapeutics Company Detail
Table 114. Onconova Therapeutics Business Overview
Table 115. Onconova Therapeutics Myelodysplastic Syndrome (MDS) Treatment Product
Table 116. Onconova Therapeutics Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 117. Onconova Therapeutics Recent Development
Table 118. Astex Pharmaceutical Company Detail
Table 119. Astex Pharmaceutical Business Overview
Table 120. Astex Pharmaceutical Myelodysplastic Syndrome (MDS) Treatment Product
Table 121. Astex Pharmaceutical Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 122. Astex Pharmaceutical Recent Development
Table 123. Helsinn Healthcare SA Company Detail
Table 124. Helsinn Healthcare SA Business Overview
Table 125. Helsinn Healthcare SA Myelodysplastic Syndrome (MDS) Treatment Product
Table 126. Helsinn Healthcare SA Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 127. Helsinn Healthcare SA Recent Development
Table 128. Abbott Company Detail
Table 129. Abbott Business Overview
Table 130. Abbott Myelodysplastic Syndrome (MDS) Treatment Product
Table 131. Abbott Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 132. Abbott Recent Development
Table 133. Boehringer Ingelheim International GmbH, Company Detail
Table 134. Boehringer Ingelheim International GmbH, Business Overview
Table 135. Boehringer Ingelheim International GmbH, Myelodysplastic Syndrome (MDS) Treatment Product
Table 136. Boehringer Ingelheim International GmbH, Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 137. Boehringer Ingelheim International GmbH, Recent Development
Table 138. Johnson & Johnson Private Limited. Company Detail
Table 139. Johnson & Johnson Private Limited. Business Overview
Table 140. Johnson & Johnson Private Limited. Myelodysplastic Syndrome (MDS) Treatment Product
Table 141. Johnson & Johnson Private Limited. Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 142. Johnson & Johnson Private Limited. Recent Development
Table 143. MEI Pharma Inc. Company Detail
Table 144. MEI Pharma Inc. Business Overview
Table 145. MEI Pharma Inc. Myelodysplastic Syndrome (MDS) Treatment Product
Table 146. MEI Pharma Inc. Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 147. MEI Pharma Inc. Recent Development
Table 148. Aprea Therapeutics Company Detail
Table 149. Aprea Therapeutics Business Overview
Table 150. Aprea Therapeutics Myelodysplastic Syndrome (MDS) Treatment Product
Table 151. Aprea Therapeutics Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 152. Aprea Therapeutics Recent Development
Table 153. Reddy's Laboratories Ltd. Company Detail
Table 154. Reddy's Laboratories Ltd. Business Overview
Table 155. Reddy's Laboratories Ltd. Myelodysplastic Syndrome (MDS) Treatment Product
Table 156. Reddy's Laboratories Ltd. Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 157. Reddy's Laboratories Ltd. Recent Development
Table 158. AbbVie Inc. Company Detail
Table 159. AbbVie Inc. Business Overview
Table 160. AbbVie Inc. Myelodysplastic Syndrome (MDS) Treatment Product
Table 161. AbbVie Inc. Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 162. AbbVie Inc. Recent Development
Table 163. Syros Pharmaceuticals Company Detail
Table 164. Syros Pharmaceuticals Business Overview
Table 165. Syros Pharmaceuticals Myelodysplastic Syndrome (MDS) Treatment Product
Table 166. Syros Pharmaceuticals Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 167. Syros Pharmaceuticals Recent Development
Table 168. Acceleron Pharma, Inc. Company Detail
Table 169. Acceleron Pharma, Inc. Business Overview
Table 170. Acceleron Pharma, Inc. Myelodysplastic Syndrome (MDS) Treatment Product
Table 171. Acceleron Pharma, Inc. Revenue in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024) & (US$ Million)
Table 172. Acceleron Pharma, Inc. Recent Development
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myelodysplastic Syndrome (MDS) Treatment Market Size Comparison by Type (2024-2029) & (US$ Million)
Figure 2. Global Myelodysplastic Syndrome (MDS) Treatment Market Share by Type: 2022 VS 2029
Figure 3. Azacitidine Features
Figure 4. Lenalidomide Features
Figure 5. Decitabine Features
Figure 6. Deferasirox Features
Figure 7. Global Myelodysplastic Syndrome (MDS) Treatment Market Size Comparison by Application (2024-2029) & (US$ Million)
Figure 8. Global Myelodysplastic Syndrome (MDS) Treatment Market Share by Application: 2022 VS 2029
Figure 9. Refractory Cytopenia with Unilineage Dysplasia Case Studies
Figure 10. Refractory Anemia with Ringed Sideroblasts Case Studies
Figure 11. Others Case Studies
Figure 12. Myelodysplastic Syndrome (MDS) Treatment Report Years Considered
Figure 13. Global Myelodysplastic Syndrome (MDS) Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Myelodysplastic Syndrome (MDS) Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Myelodysplastic Syndrome (MDS) Treatment Market Share by Region: 2022 VS 2029
Figure 16. Global Myelodysplastic Syndrome (MDS) Treatment Market Share by Players in 2022
Figure 17. Global Top Myelodysplastic Syndrome (MDS) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome (MDS) Treatment as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Myelodysplastic Syndrome (MDS) Treatment Revenue in 2022
Figure 19. North America Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Myelodysplastic Syndrome (MDS) Treatment Market Share by Country (2018-2029)
Figure 21. United States Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Canada Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Myelodysplastic Syndrome (MDS) Treatment Market Share by Country (2018-2029)
Figure 25. Germany Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. France Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. U.K. Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Italy Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Russia Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Nordic Countries Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Share by Region (2018-2029)
Figure 33. China Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Japan Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. South Korea Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. India Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Australia Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Myelodysplastic Syndrome (MDS) Treatment Market Share by Country (2018-2029)
Figure 41. Mexico Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Brazil Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Market Share by Country (2018-2029)
Figure 45. Turkey Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Saudi Arabia Myelodysplastic Syndrome (MDS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Novartis AG Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 48. Celgene Corporation Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 49. Otsuka Pharmaceutical Co., Ltd Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 50. Sandoz Inc Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 51. Dr Reddys Laboratories Limited Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 52. Pharmascience Inc Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 53. Accord Healthcare Ltd Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 54. Mylan N.V. Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 55. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 56. Bristol-Myers Squibb Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 57. LUPIN Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 58. Pfizer Inc Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 59. Amgen Inc Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 60. Onconova Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 61. Astex Pharmaceutical Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 62. Helsinn Healthcare SA Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 63. Abbott Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 64. Boehringer Ingelheim International GmbH, Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 65. Johnson & Johnson Private Limited. Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 66. MEI Pharma Inc. Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 67. Aprea Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 68. Reddy's Laboratories Ltd. Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 69. AbbVie Inc. Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 70. Syros Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 71. Acceleron Pharma, Inc. Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Treatment Business (2018-2024)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries